Methods A disproportionality analysis was conducted using post-marketing data from the FAERS repository (2018 Q1 to 2022 Q4)
Summary Musculoskeletal complaints on tirzepatide affect a minority but are consistent across datasets, with a postmarketing review finding 15% of 500 patients reporting body aches and other clinical samples reporting between 5% and 10% for related muscle symptoms
No documented direct drug interactions exist between semaglutide (Wegovy) and typical cold remedy ingredients such as paracetamol, antihistamines, or decongestants
Semaglutide intervention affects the biosynthesis of phenylalanine, tyrosine, and tryptophan, phenylalanine metabolism, arginine biosynthesis, and arginine and proline metabolism
For regular oral contraceptives, the manufacturer recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after tirzepatide initiation and for four weeks after each dose escalation
Poor lifestyle choices may result in some or all of the weight regained